Grifols SA
MAD:GRF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Grifols SA
MAD:GRF
|
ES |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
US |
|
S
|
Site Centers Corp
SWB:DDR2
|
US |
|
Sanlam Ltd
OTC:SLMAF
|
ZA |
|
CK Asset Holdings Ltd
HKEX:1113
|
HK |
|
China Vanke Co Ltd
HKEX:2202
|
CN |
|
C
|
Charter Hall Group
OTC:CTOUF
|
AU |
|
U
|
Unum Group
LSE:0LJN
|
US |
|
SunCoke Energy Inc
NYSE:SXC
|
US |
|
F
|
Far East Hospitality Trust
SGX:Q5T
|
SG |
|
U
|
United Labels AG
XHAM:ULC
|
DE |
|
Takashimaya Co Ltd
TSE:8233
|
JP |
Grifols SA
Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines. Its customers are hospitals, clinics, pharmacies, blood banks, and medical laboratories. Grifols makes money by selling finished therapies, diagnostic reagents, and testing instruments, and by supplying products and services tied to plasma collection and blood testing. A large part of the business depends on turning donated plasma into specialized treatments that are hard to make and heavily regulated. What makes Grifols different is that it sits in several parts of the healthcare value chain at once. It collects plasma, processes it into medicines, and also sells diagnostic equipment that helps screen blood and support laboratory testing. That mix gives it a role both as a drug maker and as a supplier to the blood and diagnostics industry.
Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.
Its customers are hospitals, clinics, pharmacies, blood banks, and medical laboratories. Grifols makes money by selling finished therapies, diagnostic reagents, and testing instruments, and by supplying products and services tied to plasma collection and blood testing. A large part of the business depends on turning donated plasma into specialized treatments that are hard to make and heavily regulated.
What makes Grifols different is that it sits in several parts of the healthcare value chain at once. It collects plasma, processes it into medicines, and also sells diagnostic equipment that helps screen blood and support laboratory testing. That mix gives it a role both as a drug maker and as a supplier to the blood and diagnostics industry.
On track: Grifols said second quarter results were in line with expectations and that the company remains on track to deliver full-year 2026 guidance.
Revenue growth: First-half revenue reached EUR 3,574 million, up 2.6% at constant currency, led by Biopharma, which grew 5.4%.
Profitability: Adjusted EBITDA came in at EUR 472 million in Q2 and EUR 854 million in the first half, with management reaffirming a full-year adjusted EBITDA margin target of 25% or higher.
Cash flow: Free cash flow improved by about EUR 100 million in the first half, and management kept full-year free cash flow guidance unchanged at EUR 500 million to EUR 575 million pre-M&A.
Growth drivers: Strong immunoglobulin demand, improving alpha-1 and specialty proteins, and early benefits from Egypt and U.S. center closures are expected to support the second half.
Strategic shift: Grifols highlighted its Diagnostics repositioning, the launch of Evanzys IH, and ongoing preparations for a potential IPO of its U.S. Biopharma business.
